A summary of announcements/highlights from #AGBT23 (in no particular order):
#AGBT23 cfDNA methylation profiling as a blood biomarker for Congestive Heart Failure. This is from the same team that gave you the @GrailBio Methylation Atlas, now applied to biomarker discovery. genomeweb.com/sequencing/agb…
#AGBT23 Miga on the comparison between PacBio Revio and Oxford @nanopore High Duplex / UltraLong reads. PacBio 21/46 T2T and ONT 24/46 (higher is better). Ultralong reads scaffolding for both (unconfirmed) would mean ONT lead is even bigger.
#AGBT23 Nebula Genomics announces the $175 "Deep genome" offering. The caveat is that it requires a subscription which puts the total up to $450. That's the first sub-$200 genome 30x direct to consumer offering, discounting the subscription.
#AGBT23 Illumina Infinity reads are indeed the Longas "noisy polymerase" method (renamed land-marking). Unconfirmed 5x mark-up in $/Gb compared to short-reads, unconfirmed 5-10kb+ DNA sequence lengths.
#AGBT23 BD Rhapsody, single cell partitioning system, microwell tech, 1 cell + 1 bead/well. Cells lysed, retrieve beads, cDNA synthesis. New HT system, 8 lane cartridge, 267k microwells, 320k cells, partial use of cartridge. 24 plex, scCITE-Seq. Unconfirmed: Celsee tech.
#AGBT23 @10xGenomics roadmap includes 5,000-plex RNA probes on Xenium imaging, and allele and Isoform mapping in situ; claim of no upper bound for density of RCA probes in situ.
#AGBT23 @10xGenomics, Chromium X/iX single cell updates, 1M > 8M cells/chip, 3', 5'-, ATAC, cell surface proteins. New 'Flex', any sample, cells fixed before analysis, 5x more multiplexing scale, more genes/cell. FFPE data looked better than frozen!
#AGBT23 @10xGenomics VisiumHD with CytAssist. Unconfirmed ETA, presumably only internal data.
#AGBT23 Both @CompleteGenomic's and @ElemBio technologies capable of paired-end sequencing of inserts of 2kb and 3kb. Unconfirmed limit of Illumina NovaSeq at ~600bp? Unconfirmed limit of Illumina NextSeq 1000/2000 could be even lower?
#AGBT23 @CompleteGenomic's DNBSEQ-T7 pricing model for 3 sequencers and reagent commitment down to $1.5/Gb or $150/genome. Announced DNBSEQ-T20 capable of sequencing 50,000 genomes a year with machine included in the reagents for <$100/genome. linkedin.com/pulse/complete…
This adds to the list of NGS offerings, nicely summarized by @LAbizar pre-#AGBT23
And final highlight, first known interaction in the world between Flo-Rida and genomicists. Unconfirmed: there will be a new music video recorded where Flo-Rida entourage is all from genomics community.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Albert Vilella

Albert Vilella Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AlbertVilella

Feb 11
The world of Next-Generation Sequencing (NGS) post-#AGBT23:
1) Some will say that $ILMN Illumina is sleep-walking into a cliff: the company has been dominating the field with 80-90%+ of the market-share, but they are unable to retain their technological advantage to competitors:
- Illumina doesn't have the most affordable $/Gb platform anymore, currently at $3.2/Gb, and $2/Gb in H2 2023, but others are already at $2/Gb, $1.5/Gb and will be at $1/Gb in Q3 2023.
- Illumina doesn't have the longest read technology, or anything near the competition in terms of read length times $/Gb. Oxford @nanopore is unmatched with their ultra-long read technology and is nearing $10/Gb Q30+ performance, as is PacBio on 15-10Kb reads.
Read 21 tweets
Feb 10
In #NextGenerationProteomics news, today we cover the basics of Proximity ligation assay (PLA) technology, also known as proximity barcoding assay technology, which is a method for detecting protein-protein interactions in cells or tissues.
The assay is based on the principle of ligating two probes (such as antibodies) that are in close proximity to each other, typically within a few nanometers. The ligation reaction produces a circular DNA molecule that is amplified by polymerase chain reaction (PCR) and
can be detected by sequencing or by fluorescence-based microarray readouts. The technology allows for the quantification of specific protein interactions in complex biological samples and can be used for a variety of applications, including drug discovery,
Read 18 tweets
Feb 9
#AGBT23 More details on the $ILMN Illumina Infinity reads technology from Alex Aravanis (post from LinkedIn).
Also first data shared on XLEAP-SBS chemistry for the NextSeq 1000/2000 instruments. Not sure why would anyone buy one of these instruments given the alternatives from @ElemBio and @CompleteGenomic 's G400.
First shipment on NovaSeq X: if Illumina can beat the competition at anything in the next few months, it'll be on manufacturing and deployment of the NovaSeq X.
Read 4 tweets
Feb 8
Given all the talk of $100 genomes and tens of thousands of genomes being sequenced per year on a single instrument, the question arises: how many of these sequencing factories are we going to see? how many genome equivalents do we need capacity for?
Taking the 50,000 genomes a year mark as a starting number, and considering we have 140 million new-borns a year, we would need 2,800 DNBSEQ T20 factories distributed around the world only to keep up with the new-born human population.
If we consider that about 10% of the world population is older than 65 years, that's 788 million people. If we rounded up to 1 billion people needing cancer screening via liquid biopsy, and estimated the sequencing needed to be 1/10th of a human genome equivalent, then
Read 8 tweets
Feb 8
In #NextGenerationSequencing, @CompleteGenomic's new of the <$100/genome with their DNBSEQ T20 available from Q3 2023, and their T7x3 $130/genome pricing, we now have 3 companies that have hit the $200/genome mark with announcements: @ElemBio $ILMN Illumina and Complete Genomics.
Both $ILMN Illumina and @CompleteGenomic's will hit the $200/genome and <$100/genome mark in the second half of 2023, but @ElemBio Element Bio AVITIx3 and Complete Genomics T7x3 pricing models are *now* available at $200/genome and $130/genome respectively.
Also @UltimaGenomics is working on their U100 instrument aiming at $100/genome, and had several announcements of partnerships with library prep providers at #AGBT23.
Read 4 tweets
Jan 13
In #JPM2023, $NAUT Nautilus Bio didn't make their slides available, but they have a slide deck from an investor meeting in December 2022. They intend to launch their Proteome Analysis Platform in Mid-2024.
They see a market opportunity of $25B, where 50% would be BioPharma customers, and 20% Academic and Research.
One of the biggest piece of news is that $NAUT Nautilus Bio recently partnered with Abcam to enhance their affinity reagent development program.
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(